eXoZymes Inc. $(EXOZ)$, a leader in AI-engineered enzymes, has reported a net loss of $2.36 million for the second quarter of 2025, contributing to a year-to-date loss of $4.22 million. This increase in net loss compared to the previous year is attributed to a $1.20 million rise in operating expenses, primarily due to expanded research and development and leadership hires aimed at driving long-term growth. The company ended the quarter with $6.99 million in cash and cash equivalents, which is expected to support operations through the first quarter of 2026. eXoZymes highlighted its selection as a core industry partner in a $9 million NSF-funded initiative, with a $3 million share to advance modular cell-free biomanufacturing and develop a production module for santalene, a high-value fragrance compound. Additionally, the company achieved a biomanufacturing breakthrough by advancing from concept to gram-scale NCT production in five months, with a 96% yield and over 99% purity.